ADR Biomedical Holdings (TSE:3750) Beneish M-Score: 65.07 (As of Jul. 09, 2026)


TSE:3750 ADR Biomedical Holdings Inc TSE:3750
30 GF Score
Price 円805.00
GF Value 円40.42
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Beneish M-Score?

ADR Biomedical Holdings TSE:3750 -1.23% 30 Beneish M-Score is 65.07 as of Jul. 09, 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 822 Biotechnology companies, ADR Biomedical Holdings ranks worse than 98.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 65.07 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for ADR Biomedical Holdings's Beneish M-Score or its related term are showing as below:

TSE:3750' s Beneish M-Score Range Over the Past 10 Years
Min: -15.37   Med: -1.37   Max: 65.07
Current: 65.07

During the past 13 years, the highest Beneish M-Score of ADR Biomedical Holdings was 65.07. The lowest was -15.37. And the median was -1.37.

ADR Biomedical Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Beneish M-Score Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.16 -2.55 -2.33 -15.37 65.07

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.33 0.00 -15.37 0.00 65.07

TSE:3750 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, ADR Biomedical Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADR Biomedical Holdings Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ADR Biomedical Holdings's Beneish M-Score falls into.


TSE:3750
30GF Score
ADR Biomedical Holdings Inc TSE:3750
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ADR Biomedical Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 70.3799+0.528 * -0.2364+0.404 * 2.8036+0.892 * 0.4172+0.115 * 0.0165
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 5.1875+4.679 * 1.053826-0.327 * 0.7823
=65.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円148.88 Mil.
Revenue was 円50.99 Mil.
Gross Profit was 円10.56 Mil.
Total Current Assets was 円350.51 Mil.
Total Assets was 円368.06 Mil.
Property, Plant and Equipment(Net PPE) was 円0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was 円0.69 Mil.
Selling, General, & Admin. Expense(SGA) was 円242.19 Mil.
Total Current Liabilities was 円226.72 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.
Net Income was 円-396.90 Mil.
Gross Profit was 円0.00 Mil.
Cash Flow from Operations was 円-784.77 Mil.
 Total Receivables was 円5.07 Mil.
Revenue was 円122.20 Mil.
Gross Profit was 円-5.98 Mil.
Total Current Assets was 円517.16 Mil.
Total Assets was 円3,537.59 Mil.
Property, Plant and Equipment(Net PPE) was 円2,960.26 Mil.
Depreciation, Depletion and Amortization(DDA) was 円49.58 Mil.
Selling, General, & Admin. Expense(SGA) was 円111.90 Mil.
Total Current Liabilities was 円491.75 Mil.
Long-Term Debt & Capital Lease Obligation was 円2,293.90 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(148.881 / 50.988) / (5.07 / 122.204)
=2.919922 / 0.041488
=70.3799

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-5.983 / 122.204) / (10.561 / 50.988)
=-0.048959 / 0.207127
=-0.2364

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (350.509 + 0) / 368.058) / (1 - (517.163 + 2960.264) / 3537.592)
=0.04768 / 0.017007
=2.8036

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=50.988 / 122.204
=0.4172

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(49.576 / (49.576 + 2960.264)) / (0.693 / (0.693 + 0))
=0.016471 / 1
=0.0165

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(242.192 / 50.988) / (111.897 / 122.204)
=4.74998 / 0.915657
=5.1875

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 226.721) / 368.058) / ((2293.903 + 491.751) / 3537.592)
=0.615993 / 0.787444
=0.7823

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-396.904 - 0 - -784.773) / 368.058
=1.053826

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ADR Biomedical Holdings has a M-score of 65.07 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 65.07 mean?
ADR Biomedical Holdings (TSE:3750) has a Beneish M-Score of 65.07 as of Jul. 09, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #809 out of 822 companies in the Biotechnology industry, placing it in the top 98.4%.
Is ADR Biomedical Holdings' Beneish M-Score too high?
ADR Biomedical Holdings' current Beneish M-Score is 65.07. Based on the distribution chart, ADR Biomedical Holdings ranks #809 out of 822 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #809 out of 822 companies for Beneish M-Score. This places ADR Biomedical Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Beneish M-Score is 65.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current Beneish M-Score is 65.07. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Beneish M-Score is 65.07 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Beneish M-Score: 65.07
  • GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score

Get the complete analysis for TSE:3750

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円805.00
Price
円40.42
GF Value